Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Non-Current Assets: 2015-2025

Historic Non-Current Assets for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to $91.9 million.

  • Seres Therapeutics' Non-Current Assets fell 13.11% to $91.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.9 million, marking a year-over-year decrease of 13.11%. This contributed to the annual value of $101.1 million for FY2024, which is 44.79% down from last year.
  • According to the latest figures from Q3 2025, Seres Therapeutics' Non-Current Assets is $91.9 million, which was down 3.33% from $95.1 million recorded in Q2 2025.
  • Over the past 5 years, Seres Therapeutics' Non-Current Assets peaked at $183.2 million during Q4 2023, and registered a low of $37.5 million during Q3 2021.
  • For the 3-year period, Seres Therapeutics' Non-Current Assets averaged around $135.1 million, with its median value being $153.3 million (2023).
  • Per our database at Business Quant, Seres Therapeutics' Non-Current Assets spiked by 200.64% in 2022 and then crashed by 44.85% in 2025.
  • Over the past 5 years, Seres Therapeutics' Non-Current Assets (Quarterly) stood at $51.2 million in 2021, then soared by 200.64% to $154.0 million in 2022, then increased by 18.94% to $183.2 million in 2023, then slumped by 44.79% to $101.1 million in 2024, then fell by 13.11% to $91.9 million in 2025.
  • Its Non-Current Assets was $91.9 million in Q3 2025, compared to $95.1 million in Q2 2025 and $98.1 million in Q1 2025.